1.Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.
Santos García D1, Martínez Castrillo JC2, Puente Périz V3, Seoane Urgorri A4, Fernández Díez S5, Benita León V6, Udaeta Baldivieso B7, Campolongo Perillo A8,9, Mariscal Pérez N10. Neurodegener Dis Manag. 2016 Apr 14. [Epub ahead of print]
Patients with Parkinson's disease often have a good initial response to dopaminergic therapy but later usually develop motor fluctuations and dyskinesia. In these patients, continuous infusion of levodopa-carbidopa intestinal gel (LCIG) allows for maintaining adequate dopamine levels and for improving motor and nonmotor symptoms, as well as quality of life and autonomy. Adequate candidate selection and follow-up are crucial for treatment success. Management should be multidisciplinary, and patient and caregiver education is a priority. This expert consensus document has been developed by a team of neurologists, gastroenterologists and nurses who have a vast experience in LCIG therapy, with an intention to provide knowledge and tools to facilitate patient management throughout all phases of LCIG treatment process.
2.Efficiency of the occlusion therapy with and without levodopa-carbidopa in amblyopic children-A tertiary care centre experience.
Sofi IA1, Gupta SK2, Bharti A3, Tantry TG4. Int J Health Sci (Qassim). 2016 Apr;10(2):249-57.
OBJECTIVES: To assess the role, efficacy and tolerability of levodopa-carbidopa in the management of small and older children with different types of amblyopia.
3.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K1,2, Odin P3,4, Nyholm D5. CNS Drugs. 2016 Apr 30. [Epub ahead of print]
BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) is available in several countries for the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor fluctuations and dyskinesia when other treatments have not given satisfactory results.
4.Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Dhall R1, Kreitzman DL2. Neurology. 2016 Apr 5;86(14 Suppl 1):S13-24. doi: 10.1212/WNL.0000000000002510. Epub 2016 Apr 4.
Parkinson disease (PD) is a slowly progressive, incurable, neurodegenerative disorder with progressive motor symptoms that can be managed with treatments. Levodopa is generally recognized as the most effective and widely used treatment for PD. It improves function and quality of life, morbidity, and mortality, and therefore reduces individual and societal costs. Levodopa has a relatively short half-life, however, and is quickly metabolized in the plasma, leading to fluctuations, including wearing-off of effect and inconsistent symptomatic relief as well as development of dyskinesias, with both wearing off and dyskinesias worsening with advancing disease. Immediate-release and controlled-release formulations have been used with success, but motor fluctuations remain a problem. RYTARY (levodopa and carbidopa, IPX066) is an oral extended-release therapy composed of carbidopa-levodopa microbeads designed to dissolve at various rates that allows for quick absorption and sustained levodopa release over an extended period.
